03.04.2017 • News

Azelis Signs Two Distribution Deals

(c) Lichtmeister/Shutterstock
(c) Lichtmeister/Shutterstock

German specialty chemicals distributor Azelis has signed two new agreements, both with US-based producers. Financial details were not disclosed. Under the first deal, it will supply a range of phenoxy resins in Europe for Gabriel Performance Products. The agreement, which came into effect in 2016, was extended to include the mercaptans range of epoxy curing agents as of February 2017.

Ashtabula, Ohio-based Gabriel is recognized as the world’s leading provider of phenoxy resins and the only authorized source in Europe, said Michel Dumusois, Azelis’s market segment director CASE [coatings, adhesives, sealants, elastomers]. Jeff Gates, Gabriel’s vice president, marketing, said the partners have a long history of working together, and Azelis is a natural fit to present Gabriel’s brands in Europe. Gabriel boosted its phenoxy product portfolio with the acquisition of InChem Corporation on Dec. 31, 2015.

Azelis’ second agreement is with US industrial additive supplier Elco Corp. Under the terms of this acquisition, Azelis will distribute Elco’s lubricants and metal working fluids in Germany, Austria, Switzerland, Greece and Turkey. Many of Elco’s key products are stored at Azelis’s warehouse in Germany, which the distributor said offers customers short lead times without a minimum order quantity.

Javier Miranda, lubricants & metal working fluid market segment manager, Azelis, said Elco complements its existing portfolio for the industrial lubricants market, in which technical, performance and safety demands are increasing.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read